Enclomiphene Citrate Self-Injection Technique: Why This Oral Drug Does Not Require Injections

Enclomiphene Is Not an Injectable: Clearing Up the Confusion

Enclomiphene citrate is administered orally as a capsule or tablet, taken once daily with or without food. There is no injectable formulation of enclomiphene available for clinical or compounding use. The search for "self-injection technique" likely reflects confusion between enclomiphene and injectable testosterone replacement therapy (TRT), which does require subcutaneous or intramuscular injection.

The confusion makes sense. Many men diagnosed with secondary hypogonadism are initially offered testosterone cypionate injections, typically 100 to 200 mg intramuscularly every one to two weeks. That protocol demands injection-site rotation, needle selection (typically 22- to 25-gauge for IM, 27- to 30-gauge for subcutaneous), and sharps disposal. Enclomiphene eliminates all of that. You take a pill.

This distinction matters beyond convenience. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis through negative feedback, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) output. The downstream result: testicular atrophy and suppressed spermatogenesis. A 2019 review published in Translational Andrology and Urology found that exogenous testosterone can reduce sperm concentration to azoospermic levels in a significant proportion of men within 6 months of initiation. Enclomiphene takes the opposite approach.

How Enclomiphene Citrate Works: Mechanism of Action

Enclomiphene selectively blocks estrogen receptors in the hypothalamus and anterior pituitary, removing the negative feedback that estradiol normally exerts on gonadotropin secretion. This triggers increased pulsatile release of gonadotropin-releasing hormone (GnRH), which in turn stimulates the pituitary to secrete more LH and FSH.

LH drives Leydig cell testosterone production. FSH supports Sertoli cell function and spermatogenesis. The result is a rise in endogenous testosterone without the gonadotropin suppression caused by injecting exogenous hormone.

Enclomiphene is the trans-isomer of clomiphene citrate. Standard clomiphene (Clomid) is a racemic mixture of two isomers: enclomiphene (trans) and zuclomiphene (cis). The distinction is pharmacologically significant. Zuclomiphene has a half-life exceeding one week and accumulates with repeated dosing, contributing to estrogenic side effects such as visual disturbances, mood changes, and hot flashes. Enclomiphene, isolated from its cis-isomer, has a shorter half-life (approximately 10 hours) and a cleaner anti-estrogenic profile at the hypothalamus.

Kim et al. published a key study in BJU International (2016) examining enclomiphene in men with secondary hypogonadism. The study demonstrated that enclomiphene restored serum testosterone to eugonadal levels while preserving sperm parameters, a dual outcome that injectable testosterone cannot achieve. Mean testosterone levels increased from baseline hypogonadal values (<300 ng/dL) to the mid-normal range (450 to 600 ng/dL) within weeks of oral dosing.

How to Take Enclomiphene Citrate Correctly

Since there is no injection involved, proper oral administration technique is straightforward. Take the prescribed dose (typically 12.5 mg or 25 mg) once daily, at approximately the same time each morning. The capsule can be taken with or without food, though some clinicians recommend taking it with a small meal to reduce occasional GI discomfort.

A few specific instructions matter. Do not crush or open the capsule unless your compounding pharmacist has specifically formulated it for that purpose. Missed doses should be taken as soon as remembered the same day, but do not double up the next morning. Consistency of timing supports stable gonadotropin pulsatility.

Compounding pharmacy formulations vary. Because enclomiphene citrate is not currently available as an FDA-approved standalone product, it is dispensed through 503A and 503B compounding pharmacies under a physician's prescription. The Endocrine Society's 2018 clinical practice guidelines on testosterone therapy in men with hypogonadism acknowledge clomiphene citrate as an off-label option for men who wish to preserve fertility, though they note that enclomiphene specifically awaits formal regulatory approval.

Capsule appearance, filler ingredients, and dissolution characteristics can differ between compounding sources. Patients should verify their pharmacy holds appropriate state licensure and follows USP 795 or USP 800 standards.

Enclomiphene vs. Injectable Testosterone: A Direct Comparison

The decision between enclomiphene and injectable testosterone is not simply about needle avoidance. It reflects a fundamentally different endocrine strategy.

Injectable testosterone (cypionate, enanthate, or undecanoate) delivers exogenous hormone directly into the bloodstream. Testosterone levels rise rapidly, often reaching supraphysiologic peaks 24 to 48 hours post-injection before declining toward trough levels. This sawtooth pattern can cause mood fluctuations, energy variability, and erythrocytosis. A meta-analysis published in The Journal of Clinical Endocrinology & Metabolism found that testosterone replacement therapy increased hematocrit above 54% in approximately 5% to 20% of men, depending on formulation and dose.

Enclomiphene produces a more physiologic testosterone profile. Because the testes produce testosterone in response to endogenous LH pulses, diurnal variation is maintained. There is no post-injection spike.

Three differences stand out clinically:

Fertility. This is the primary differentiator. The American Urological Association's 2018 position statement on testosterone therapy and fertility explicitly warns that exogenous testosterone should not be used in men desiring fertility. Enclomiphene, by contrast, increases FSH and supports spermatogenesis.

Testicular volume. Men on exogenous testosterone commonly experience testicular atrophy due to suppressed gonadotropins. Enclomiphene maintains or increases testicular volume by preserving the LH/FSH signal.

Hematocrit risk. Polycythemia (hematocrit >54%) is a well-documented risk of injectable testosterone, sometimes requiring therapeutic phlebotomy or dose reduction. Enclomiphene's effect on erythropoiesis appears lower because testosterone levels do not reach the supraphysiologic peaks typical of injection-day surges, though formal head-to-head hematocrit data remain limited.

The tradeoff: enclomiphene may not achieve the same absolute testosterone levels as high-dose injectable TRT. Men with primary hypogonadism (testicular failure) will not respond to enclomiphene because the testes cannot produce testosterone regardless of gonadotropin stimulation.

Who Is a Candidate for Enclomiphene

Enclomiphene is prescribed off-label for men with secondary hypogonadism, a condition where the hypothalamus or pituitary underproduces gonadotropins, leading to low testosterone despite intact testicular function. Diagnosis requires at least two morning total testosterone measurements below 300 ng/dL, combined with low or inappropriately normal LH and FSH levels, per the Endocrine Society's 2018 guidelines.

Ideal candidates share several characteristics. They have confirmed secondary (not primary) hypogonadism. They wish to preserve fertility or testicular volume. They prefer oral dosing over injections. They have baseline hematocrit below 48% and no contraindications to SERMs such as a history of venous thromboembolism.

Enclomiphene is not appropriate for men with primary testicular failure (elevated LH/FSH with low testosterone), as the mechanism depends on functional Leydig cells. It is also not recommended for men with a known history of deep vein thrombosis or pulmonary embolism, because SERMs carry a class-associated thromboembolic risk, though the absolute incidence in men at standard doses appears low.

"For younger men with hypogonadism who want to maintain fertility, clomiphene citrate or its enclomiphene isomer represents a first-line pharmacologic option before considering exogenous testosterone," states the Endocrine Society's 2018 Clinical Practice Guideline on Testosterone Therapy.

Monitoring While on Enclomiphene

Baseline labs should include total testosterone (drawn before 10 AM), free testosterone, LH, FSH, estradiol, complete blood count (CBC), comprehensive metabolic panel, and a lipid panel. A semen analysis is appropriate for men concerned about fertility.

Follow-up labs are typically drawn at 6 weeks, 12 weeks, and then every 3 to 6 months. The target is a total testosterone between 450 and 700 ng/dL with concurrent improvement in symptoms (energy, libido, body composition). If testosterone fails to rise above 400 ng/dL after 8 to 12 weeks at the maximum dose, the diagnosis may need reevaluation. Possible explanations include unrecognized primary hypogonadism, poor medication absorption, or a compounded product with inadequate potency.

Estradiol monitoring is particularly relevant. Because enclomiphene increases endogenous testosterone, aromatase converts a portion to estradiol. Some men experience estradiol-related symptoms (breast tenderness, water retention) if levels exceed approximately 40 to 50 pg/mL. Dose adjustment or the addition of a low-dose aromatase inhibitor may be considered, though routine AI co-prescription is not supported by current evidence.

"We recommend monitoring hematocrit at baseline, at 3 to 6 months, and then annually during testosterone therapy," per the Endocrine Society guideline. While this recommendation was written for exogenous testosterone, the same principle applies to any intervention that raises serum testosterone.

Side Effects and Safety Considerations

Enclomiphene is generally well tolerated at doses of 12.5 to 25 mg daily. The most commonly reported side effects include headache, nausea, and transient visual changes (blurring, floaters). Visual symptoms occur less frequently with enclomiphene alone than with racemic clomiphene, likely due to the absence of zuclomiphene accumulation.

Thromboembolic events remain a theoretical concern for all SERMs. Tamoxifen, the most studied SERM, carries an approximate 1% annual risk of venous thromboembolism in women. Data in men using enclomiphene are too sparse to generate reliable incidence figures. Prescribers should assess baseline VTE risk using the Caprini or Padua score in higher-risk patients.

Liver function abnormalities are rare but documented with clomiphene use. Periodic hepatic panel monitoring (ALT, AST) is reasonable during the first year. No cases of clinically significant hepatotoxicity have been attributed specifically to enclomiphene in the published literature.

Bone mineral density effects are worth noting. Estrogen is protective for male bone health. Because enclomiphene blocks hypothalamic estrogen receptors but does not reduce circulating estradiol (it actually increases it through enhanced aromatization of higher testosterone), the net effect on bone mineral density appears neutral to favorable. Long-term data (>2 years) are lacking.

The Regulatory Status of Enclomiphene

Enclomiphene citrate was developed by Repros Therapeutics under the brand name Androxal. The company submitted a New Drug Application (NDA) to the FDA, but the FDA issued a Complete Response Letter in 2015, requesting additional clinical data. The NDA was never resubmitted, and Repros Therapeutics was subsequently acquired.

As of 2026, enclomiphene remains available exclusively through compounding pharmacies. It is not on the FDA's list of approved drugs, nor has it been placed on the FDA's Demonstrable Difficulty list for compounding. Prescribers write prescriptions for it as an off-label compounded preparation.

This regulatory limbo has practical consequences. Insurance coverage is virtually nonexistent. Patients pay out of pocket, typically $30 to $90 per month depending on the compounding pharmacy. Potency and bioavailability can vary between pharmacies unless third-party certificate-of-analysis testing is performed.

Patients considering enclomiphene should discuss with their prescriber whether the compounding pharmacy provides potency verification via high-performance liquid chromatography (HPLC) or equivalent assay.

If You Actually Need Injection Training: When TRT Is the Right Choice

Some men do require injectable testosterone. Primary hypogonadism, severe symptomatic hypogonadism unresponsive to SERMs, or situations where fertility is not a concern may make testosterone cypionate or enanthate the better option. If your prescriber has started you on injectable TRT, proper self-injection technique matters.

For intramuscular injection (vastus lateralis or ventrogluteal site), the standard protocol uses a 22- to 25-gauge, 1- to 1.5-inch needle. For subcutaneous injection (abdominal fat pad or thigh), a 27- to 30-gauge, 0.5-inch insulin syringe is appropriate. The CDC's injection safety guidelines provide general principles for safe self-administration: hand hygiene, single-use needles, proper sharps disposal, and site rotation.

Men on injectable TRT who wish to transition to enclomiphene should not stop injections abruptly. The HPG axis may require 4 to 12 weeks to recover gonadotropin pulsatility after exogenous testosterone suppression. A supervised taper, sometimes bridged with human chorionic gonadotropin (hCG), is recommended under physician guidance.

Baseline semen analysis before and 3 months after the switch helps track spermatogenic recovery.